Jin Li

16PUBLICATIONS
66CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Diagnostic radiographyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 21, 2026
Fruquintinib: Mechanism of Action, Clinical, and Translational Science.

|May 13, 2026
Dual targeting of chemoresistance and ferroptosis in gastric cancer: DDR1/VEGFR2 inhibitor K-13 synergizes with docetaxel from preclinical models to phase Ib/II clinical trial.

|Apr 28, 2026
The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.

|Apr 10, 2026
DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages.

Xiaofan Duan, Gaoshaer Yeerkenbieke, Yanjun Feng

|Mar 04, 2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Tianshu Liu, Suxia Luo, Xianglin Yuan

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

Pageof 3

Frequent Collaborators

2 joint publications

Tianshu Liu

2 joint publications

Ying Cheng

2 joint publications

Jiuli Zhou

2 joint publications

Ying Yuan